Shares of Bioventus Inc. (BVS) surged 8.54% in pre-market trading on Tuesday following the release of better-than-expected third-quarter financial results and reaffirmation of its full-year 2025 guidance. The medical device company, which specializes in active healing innovations, demonstrated solid organic growth and improved profitability, instilling confidence in investors.

Bioventus reported Q3 revenue of $138.7 million, slightly surpassing analyst expectations of $138.2 million. The company's adjusted earnings per share came in at $0.15, significantly beating the consensus estimate of $0.12. Notably, Bioventus achieved impressive organic revenue growth of 8.2% year-over-year, driven by strong performance across all three areas of its portfolio.

Rob Claypoole, Bioventus President and Chief Executive Officer, commented on the results, stating, "Momentum continued to build across our portfolio as our team delivered an exceptional quarter reflecting above-market organic revenue growth, increased profitability, and significant cash flow acceleration." The company's focus on operational efficiency was evident in its improved Adjusted EBITDA, which increased 12.9% to $26.6 million, with the Adjusted EBITDA margin expanding to 19.2% from 17.0% in the prior-year period.

Adding to investor optimism, Bioventus reaffirmed its full-year 2025 financial guidance. The company continues to expect net sales between $560 million and $570 million, representing organic growth of approximately 6.1% to 8.0%. Additionally, Bioventus projects Adjusted EBITDA in the range of $112 million to $116 million and non-GAAP EPS between $0.64 and $0.68 for the year. This reaffirmed outlook, coupled with the strong Q3 performance, appears to have boosted confidence in Bioventus' growth trajectory and financial stability, contributing to the significant pre-market stock price increase.